Cover Image

A Population Pharmacokinetic and Pharmacodynamic Model of CKD-519

CKD-519 is a selective and potent cholesteryl ester transfer protein (CETP) inhibitor that is being developed for dyslipidemia. Even though CKD-519 has shown potent CETP inhibition, the exposure of CKD-519 was highly varied, depending on food and dose. For highly variable exposure drugs, it is cruci...

Full description

Saved in:

Bibliographic Details
Main Authors:	Choon Ok Kim (Author), Sangil Jeon (Author), Seunghoon Han (Author), Min Soo Park (Author), Dong-Seok Yim (Author)
Format:	Book
Published:	MDPI AG, 2020-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Quantitative Prediction of Human Pharmacokinetics and Pharmacodynamics of CKD519, a Potent Inhibitor of Cholesteryl Ester Transfer Protein (CETP)
by: Suein Choi, et al.
Published: (2019)

Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects
by: Kim CO, et al.
Published: (2016)

Population pharmacokinetic‐pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study
by: Yun Seob Jung, et al.
Published: (2024)

Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals
by: Guoliang Deng, et al.
Published: (2023)

Pharmacokinetic and pharmacodynamic drug-drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
by: Dasohm Kim, et al.
Published: (2023)

Pharmacokinetics, pharmacodynamics, and safety of izuforant, an H4R inhibitor, in healthy subjects: A phase I single and multiple ascending dose study
by: Byung Hak Jin, et al.
Published: (2024)

Population Pharmacokinetics of Primaquine in the Korean Population
by: Woo-Yul Lee, et al.
Published: (2021)

In vivo pharmacokinetic and pharmacodynamic study of co-spray-dried inhalable pirfenidone microparticles in rats
by: Ji-Hyun Kang, et al.
Published: (2022)

Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects
by: Hong T, et al.
Published: (2015)

Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population
by: Bing Chen, et al.
Published: (2022)

Usefulness of Bnet, a Simple Linear Metric in Discerning Torsades De Pointes Risks in 28 CiPA Drugs
by: Sungpil Han, et al.
Published: (2019)

Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants
by: Orestis Papasouliotis, et al.
Published: (2022)

Pharmacokinetic Modeling of Bepotastine for Determination of Optimal Dosage Regimen in Pediatric Patients with Allergic Rhinitis or Urticaria
by: Sukyong Yoon, et al.
Published: (2024)

Concept and utility of population pharmacokinetic and pharmacokinetic/pharmacodynamic models in drug development and clinical practice
by: Roganović Maša, et al.
Published: (2021)

Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban
by: Minsoo Kim, et al.
Published: (2019)

Population Pharmacokinetic/Pharmacodynamic Modeling of Methylprednisolone in Neonates Undergoing Cardiopulmonary Bypass
by: Christoph P. Hornik, et al.
Published: (2019)

Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
by: Jeon I, et al.
Published: (2021)

Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors
by: Hark Kyun Kim, et al.
Published: (2020)

Alfaxalone population pharmacokinetics in the rat: Model application for pharmacokinetic and pharmacodynamic design in inbred and outbred strains and sexes
by: Kate White, et al.
Published: (2022)

Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects
by: Youwei Bi, et al.
Published: (2018)

Population Pharmacokinetic-Pharmacodynamic Analysis of a Reserpine-Induced Myalgia Model in Rats
by: Gloria M. Alfosea-Cuadrado, et al.
Published: (2024)

Population Pharmacokinetic and Pharmacodynamic Modeling of Acetazolamide in Peritoneal Dialysis Patients and Healthy Volunteers
by: Corinne Seng Yue, et al.
Published: (2013)

Population Pharmacokinetic/Pharmacodynamic Modelling of Daptomycin for Schedule Optimization in Patients with Renal Impairment
by: Teresa García-Martínez, et al.
Published: (2022)

Evaluation of pharmacokinetics of warfarin from validated pharmacokinetic-pharmacodynamic model
by: Kannan Sridharan, et al.
Published: (2021)

Pharmacokinetic-Pharmacodynamic Modeling of Midazolam in Pediatric Surgery
by: Carmen Flores-Pérez, et al.
Published: (2023)

Toward Model-Informed Precision Dosing for Remimazolam: A Population Pharmacokinetic-Pharmacodynamic Analysis
by: Yueting Chen, et al.
Published: (2024)

Population pharmacokinetics, enzyme occupancy, and pharmacodynamic modeling of soticlestat in patients with developmental and epileptic encephalopathies
by: Wei Yin, et al.
Published: (2024)

Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjects
by: Rambiritch V, et al.
Published: (2016)

Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic Model
by: Jurij Aguiar Zdovc, et al.
Published: (2021)

Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma
by: B Wang, et al.
Published: (2017)

Janusz Mariański, Socjologia moralności, Wydawnictwo KUL, Lublin 2006, ss. 519.
by: Agnieszka Zduniak
Published: (2007)

The mIRNA519a-3p and NKG2D in endometriosis.
by: Cepi Teguh Pramayadi, et al.
Published: (2022)

The influence of telmisartan on metformin pharmacokinetics and pharmacodynamics
by: Jiagen Wen, et al.
Published: (2019)

Population Pharmacokinetics of Hydroxychloroquine and 3 Metabolites in COVID-19 Patients and Pharmacokinetic/Pharmacodynamic Application
by: Jean Claude Alvarez, et al.
Published: (2022)

Pharmacokinetic and Pharmacodynamic Characteristics of Pelubiprofen Tromethamine vs. Pelubiprofen in Healthy Subjects
by: Yu-Jeong Son, et al.
Published: (2023)

Development of Level A In Vitro-Vivo Correlation for Electrosprayed Microspheres Containing Leuprolide: Physicochemical, Pharmacokinetic, and Pharmacodynamic Evaluation
by: Dong-Seok Lee, et al.
Published: (2020)

Influence of curcumin on the pharmacodynamics and pharmacokinetics of gliclazide in animal models
by: Vatsavai LK, et al.
Published: (2016)

A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS‐114
by: Hikari Araki, et al.
Published: (2022)

Acute Kidney Injury: Clinical Characteristics and Short-Term Outcomes in 1,519 Patients
by: Christina Montgomerie, et al.
Published: (2022)

Levodopa in Parkinson's Disease: A Review of Population Pharmacokinetics/Pharmacodynamics Analysis
by: Amélie Marsot, et al.
Published: (2017)